William H. Rorer, Inc.

Cooper Laboratories, Inc.

Berlex Laboratories, Inc.

Schering Aktiengesellschaft

Key Pharmaceuticals, Inc.

Julius Diamond

George H Douglas

Ronald A Wohl

Jerome J Zalipsky

Thomas K Morgan, Jr

Norman J Santora

William C Lumma, Jr

Bernard J Burns

William L Studt

Stuart A Dodson

Ching T Tsuei

The imidazolium salts described are useful as antiarrhythmic agents. A method of treating arrhythmia by increasing the refractoriness of cardiac tissue is provided as well as pharmaceutical formulations containing such imidazolium salts.

Antiarrhythmic imidazoles

A novel, orally administrable pro-drug form of dobutamine of the formula ##STR1## or a pharmaceutically acceptable acid addition salt thereof.

Dobutamine tri-isobutyric acid ester and the use thereof as a

Antiarrhythmic imidazoliums

The imidazolium salts described are useful as antiarrhythmic agents. A method of treating arrhythmia by increasing the refractoriness of cardiac tissue is provided as well as pharmaceutical formulations containing such imidazolium salts. The compounds are described by the following formula: ##STR1##

The compound N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-1H-benzimidazole-1-butanamine and methods for its manufacture and use are described herein. The compound is a cardiotonic agent useful primarily in the treatment of congestive heart failure.

N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-1H-benzimidazole-1-butanamine and

A novel method of treating gastrointestinal, spasmolytic and ulcerogenic disorders by the administration of amidinoureas is disclosed.

Amidinoureas

Novel phenylamidinourea compounds and processes for their preparation are described. These compounds have an effective degree of anti-hypertensive properties and exert activities on the cardiovascular system. A method for the treatment of hypertensive disorders is also described.

Psoriasis is systemically treated by the administration of a salicylate which is capable of inhibiting the endogenous lipoxygenase present in psoriatic plaque fluid without the inhibition of the cyclooxygenase enzyme.

Systemic treatment of psoriasis using certain salicylates

3-Phenoxy-2-hydroxypropylamines having an N-benzimidazolyalkyl substituent and similar compounds are described herein. They are obtained by the reaction of the appropriate imidazole-1-alkanamine with an epoxide, and they are useful primarily as .beta..sub.1 -agonists/.beta.-sympathomimetic agents.

Treating cardiovascular diseases with

This invention describes a new class of 1-amidino-3-phenylthiourea and N'-phenylamidinothiourea compounds wherein the phenyl group is ortho substituted, and processes for their preparation. The phenylamidinothiourea compounds may be incorporated into pharmaceutical preparations which are useful for producing anti-ulcerogenic, antisecretory, antispasmodic, antihypertensive, anti-arrhythmic, anesthetic, antidiarrheal and antiparasitic action.

Amidinothioureas

Novel 1,2-disubstituted imidazol(in)es are described herein. The compounds are generally produced by reacting a haloacylanilide with an excess of 2-substituted-imidazol(in)e. The compounds are antiarrhythmic agents.

Method of use of antiarrhythmic 1-arylcarbamoylalkyl imidazole

Novel ethynylbenzene compounds and their derivatives which are useful for the treatment for the relief of inflammation, pain and fever.

Ethynylbenzene compounds and derivatives thereof

3-Phenoxy-2-hydroxypropylamines having an N-benzimidazolyalkyl substituent and similar compounds are described herein. They are obtained by the reaction of the appropriate imidazole-1-alkanamine with an epoxide, and they are useful primarily as .beta.-adrenergic blocking agents.

Growing community of inventors

Morris Plains, NJ, United States of America

Julius Diamond